CPT1A and cancer: Intriguingly, Singh and colleagues demonstrated that the CPT-1 inhibitor etomoxir kills cancer stem cells without side effects on normal cells, providing clear-cut evidence of cancer’s addiction to the lipid catabolism pathway [72].